Literature review analysis of aortitis induced by granulocyte-colony stimulating factor Authors: Ting Zhao, Huanhuan Xu Published: 2024 ABSTRACT BackgroundRecombinant human granulocyte-colony stimulating factors (G-CSF)-induced aortitis is a rare but particularly serious adverse event, commonly seen in cancer patients undergoing chemotherapy. The aim of this article is to clarify the clinical characteristics of G-CSF- induced aortitis and provide effective references for clinical diagnosis and intervention.MethodsCase reports of adverse reactions of aortitis induced by G-CSF were collected from the relevant databases. The patients’ basic information and adverse reaction process were recorded and subjected to descriptive analysis.ResultsA total of 72 patients were enrolled, including 14 males and 58 females, with a mean age of 61.83 ± 10.30 years. The G-CSF type with the highest frequency of occurrence of aortitis is pegfilgrastim. Apart from three healthy stem cell donors, G-CSF-induced aortitis was primarily found in patients with underlying malignancies, especially in patients with breast cancer. The most common anticancer drugs used at onset were docetaxel, cyclophosphamide, and doxorubicin. CT scan showed that aortitis most commonly occured in the aortic arch and its branches. Most patients had a good prognosis, but 3 cases developed complications. Importantly, G-CSF-induced aortitis was also found in 4 asymptomatic patients.ConclusionThis article found that G-CSF-induced aortitis not only occured in cancer patients undergoing chemotherapy as previously reported in literature, but also in healthy stem cell donors. Especially, asymptomatic patients with G-CSF-induced aortitis faced a greater risk of being missed by the attending physician. 1 Introduction Recombinant human granulocyte-colony stimulating factors (G-CSF) is a member of the hematopoietic growth factor family that mobilizes and increases peripheral blood hematopoietic stem cells in both blood donors and cancer patients. G-CSF is primarily used to promote an increase in neutrophil count during bone marrow transplantation and prevent chemotherapy-induced febrile neutropenia (Link, 2022). The common adverse reactions of G-CSF include fever, back pain, headache, bone pain, and myalgia. Severe adverse events include acute lung injury, acute coronary syndrome, and acute aortitis (D'Souza et al., 2008). According to Japanese Adverse Drug Event Report database, aortitis occurring after G-CSF administration is considered an adverse reaction of G-CSF (Oshima et al., 2019). Aortitis induced-by G-CSF is extremely rare, with an incidence rate of 0.3%–0.74% in patients with malignant neoplasms (Sasaki et al., 2021; Takamatsu et al., 2022; Lee et al., 2020). Aortitis associated with G-CSF administration primarily presents as a systemic symptoms, manifesting as fever and increased levels of c-reactive protein (CRP) (Lee et al., 2020). Due to the similarity of symptoms, it is highly likely to be misdiagnosed as an infection, thereby delaying the timely treatment of aortitis. CT is one of the crucial diagnostic tools for definitive diagnosis. Based on the cases reported to date, there are four types of G-CSF associated with aortitis, including filgrastim, lenograstim, pegfilgrastim and lipegfilgrastim. Filgrastim and lenograstim, are short-acting G-CSF, which have a similar structure and biological activity to endogenous human G-CSF (Lee et al., 2020). Pegfilgrastim and lipegfilgrastim are long-acting agent of G-CSF (Lee et al., 2020). Most notably, pegfilgrastim and filgrastim account for the majority of reported cases of aortitis. Although adverse events of arteritis caused by G-CSF have been reported in previous studies (Ito et al., 2023; Ito et al., 2024; Hoshina and Takei, 2019), adverse events of arteritis have not been described in large-scale cohort studies. In the present study, we attempted to explore distribution, occurrence and combination therapy characteristics of G-CSF-induced aortitis. To achieve this aim, we analyzed data from case reports of aortitis induced by G-CSF published in databases. 2 Materials and methods 2.1 Patients selection PubMed, MEDLINE, Embase, Web of Science, Science Direct, China National Knowledge Internet, Wan fang, and Wei Pu databases were searched until 23 March 2024. The keywords “arteritis,” “aortitis,” “large vessel vasculitis,” “adverse events,” and “granulocyte colony-stimulating factor” were used as search terms to collect case reports concerning adverse events of aortitis induced by G-CSF. The inclusion criteria were (Link, 2022) reports published in open journals and (D'Souza et al., 2008) studies including the patients’ basic information, symptoms, and treatment of adverse aortitis events. The exclusion criteria were (Link, 2022) cases repeated in the databases, and (D'Souza et al., 2008) articles with incomplete patient information, therapeutic process and prognosis of adverse events of aortitis. 2.2 Methods A literature review research design included 44 papers, was accepted to collect well-documented information (Table 1). A total of 73 cases with aortitis induced by G-CSF were collected, with one case excluded due to insufficient information. For all 72 cases, age, sex, nationality, primary disease, types of G-CSF, combined chemotherapy regimen, onset time of aortitis adverse events, symptoms, aortitis extension, clinical intervention, and outcome were recorded. The relevant data was analysed statistically. TABLE 1Detailed summary of all G-CSF-induced aortitis symptoms in patients from case report.NO.Country/YearAge/SexG-CSF Type/Treatment duration/IndicationDiagnoseTime to onset (days)TreatmentOutcome/Complication1 (Darie et al., 2004)France/200355/FFilgrastim/5 days/Blood stem cells graftHealthy stem cell donors6SteroidImprovement within 2 weeks/NO2 (Adiga et al., 2009)USA/200954/MFilgrastim/8 ds/NeutropeniaSquamous cell carcinoma of the lung13DiscontinuingImprovement within 6 days/NO3 (Miller et al., 2016)Israel/201652/MFilgrastim/4 days/Blood stem cells graftHealthy marrow donor180SteroidImprovement rapid/Aneurysm4 (Umeda et al., 2016)Japan/201678/FFilgrastim/5 years/neutropeniaCyclic neutropenia30SteroidImprovement rapid/NO5 (Sato et al., 2017)Japan/201767/FPegfilgrastim/8 days/NeutropeniaAdvanced lung adenocarcinoma1SteroidImprovement rapid/Aortic dissection6 (Parodis et al., 2018)Sweden/201870/FFilgrastim/1day/neutropeniaBreast cancer (HER2+)9SteroidImprovement rapid/NO7 (Parodis et al., 2018)Sweden/201860/FFilgrastim/1day/NeutropeniaBreast cancer (HER2+)11SteroidImprovement rapid/NO8 (Lardieri et al., 2018)Germany/2013Unknown/MPegfilgrastim/1day/NeutropeniaB cell lymphoma15Not reportedImprovement/NO9 (Lardieri et al., 2018)Japan/201649/FFilgrastim/1 day/NeutropeniaUterine cancer6NSAIDImprovement in 1 month/NO10 (Lardieri et al., 2018)Japan/201672/FPegfilgrastim/1 day/NeutropeniaUterine cancer13No treatmentImprovement in 1.5 months/NO11 (Lardieri et al., 2018)Japan/201676/FPegfilgrastim/1 day/NeutropeniaBreast cancer7No treatmentImprovement in 11 days/NO12 (Lardieri et al., 2018)Japan/201677/FFilgrastim/6 days/NeutropeniaOvarian cancer7No treatmentImprovement in 1 months/NO13 (Lardieri et al., 2018)Japan/201747/FLenograstim/“several times”/NeutropeniaOvarian cancer8SteroidResolved in 3 months/NO14 (Lardieri et al., 2018)Japan/201761/FPegfilgrastim/1day/NeutropeniaBreast cancer7SteroidResolved in 26 days; switched to filgrastim/NO15 (Lardieri et al., 2018)Japan/201762/FPegfilgrastim/1 day/NeutropeniaB cell lymphoma12SteroidResolved in 18 days/NO16 (Lardieri et al., 2018)Japan/201765/FPegfilgrastim/1 day/NeutropeniaBreast cancer9SteroidResolved in 1 month/NO17 (Lardieri et al., 2018)Japan/201766/MPegfilgrastim/1 day/NeutropeniaProstate cancer8No treatmentResolved in 1 month/NO18 (Lardieri et al., 2018)Japan/201769/FPegfilgrastim/1day/NeutropeniaEsophageal cancer11No treatmentResolved in 11 days; switched to filgrastim/NO19 (Harada et al., 2020)Japan/202052/FFilgrastim/3days/NeutropeniaOvarian cancer14SteroidImprovement rapid/NO20 (Nakamura et al., 2020)Japan/202066/FPegfilgrastim/1day/ProphylaxisBreast cancer11LoxoprofenResolved in within 3 weeks/NO21 (Soto Castillo et al., 2020)Spain/202068/FFilgrastim/3days/ProphylaxisBreast cancer5SteroidResolved in within 4 days/NO22 (Sugai et al., 2024)Japan/202055/FLenograstim/6 months, Pegfilgrastim/10 days/neutropeniaOvarian cancer10AntibioticsImprovement/NO23 (Sugai et al., 2024)Japan/202069/FLenograstim/4 months, Pegfilgrastim/15 ays/neutropeniaEndometrial cancer15No treatmentImprovement/NO24 (Sugai et al., 2024)Japan/202059/FFilgrastim/8 days/NeutropeniaEndometrial cancer8SteroidImprovement/NO25 (Sugai et al., 2024)Japan/202074/FFilgrastim/2 months, pegfilgrastim/15 days/NeutropeniaEsophageal cancer8No treatmentImprovement/NO26 (Mukai et al., 2020)Finland/201740/FLipegfilgrastim/1day/NeutropeniaBreast carcinoma10SteroidImprovement/NO27 (Mukai et al., 2020)Finland/201653/FPegfilgrastim/1day/NeutropeniaBreast carcinoma1SteroidImprovement/NO28 (Mukai et al., 2020)Finland/201856/FLipegfilgrastim/1day/NeutropeniaLobular breast carcinoma8SteroidImprovement/NO29 (Mukai et al., 2020)Finland/201870/FLipegfilgrastim/1day/NeutropeniaBreast carcinoma5SteroidImprovement/NO30 (Mukai et al., 2020)Finland/201862/FFilgrastim/3days, pegfilgrastim/3days/NeutropeniaBreast carcinoma62SteroidImprovement/NO31 (Mukai et al., 2020)Finland/201852/FFilgrastim/4days/NeutropeniaBreast carcinoma4SteroidImprovement/NO32 (Shirai et al., 2020)Japan/201966/FPegfilgrastim/1 day/prophylaxisBreast cancer10SteroidImprovement rapid/NO33 (Yamamoto et al., 2021a)Japan/202065/FPegfilgrastim/1 day/prophylaxisPancreatic cancer8No treatmentResolved in 10 days/NO34 (Yamamoto et al., 2021a)Japan/202074/FPegfilgrastim/1 day/prophylaxisTongue cancer8No treatmentResolved in 10 days/NO35 (Yamamoto et al., 2021a)Japan/202047/FPegfilgrastim/1 day/prophylaxisUterine cancer10No treatmentResolved in 14 days/NO36 (Yamamoto et al., 2021a)Japan/202043/FPegfilgrastim/1 day/prophylaxisUterine cancer7No treatmentResolved in 21 days/NO37 (Yamamoto et al., 2021b)Japan/202178/FFilgrastim/5 days/prophylaxisB cell lymphoma5SteroidResolved in 7 day/NO38 (Fujiwara et al., 2021)Japan/202149/FLenograstim/1 week/neutropeniaPinealoma7SteroidResolved in within 2 week/NO39 (Kametani et al., 2021)Japan/202166/FPegfilgrastim/7 days/neutropeniaTransverse colon adenocarcinoma2SteroidResolved in within 8 days/NO40 (Costa Silva et al., 2021)Japan/202156/MPegfilgrastim/1 day/prophylaxisExtraosseous mucinous chondrosarcoma4SteroidResolved in within 6 days/NO41 (Seto et al., 2022)Portugal/202156/FPegfilgrastim/1 day/neutropeniaBreast cancer3SteroidResolved in within 5 day/NO42 (Asif et al., 2022)Japan/202248/FPegfilgrastim/1 day/neutropeniaBreast cancer1SteroidResolved in within 15 day/NO43 (Mizushima et al., 2022)UK/202264/FPegfilgrastim/1 day/prophylaxisBreast cancer (HER2+)7SteroidResolved in within 21 days/NO44 (Arnould et al., 2023)Japan/202277/MFilgrastim/1 day/prophylaxisLung neuroendocrine tumor8SteroidImprovement rapid/NO45 (Seto et al., 2023)France/202373/FFilgrastim/4 days/neutropeniaBreast cancer5No treatmentResolved in within 45 days/NO46 (Ozaki et al., 2023)Japan/202371/MPegfilgrastim/1 day/prophylaxisLarge-cell neuroendocrine carcinoma5No treatmentImprovement rapid/NO47 (Uemura et al., 2023)Japan/202366/MPegfilgrastim/1 day/neutropeniaProstate cancer6SteroidResolved in within 3 days/NO48 (Nishioka and Fujii, 2023)Japan/202345/MFilgrastim/1 day/blood stem cells graftHealthy stem cell donors8SteroidResolved in within 10 days/NO49 (Iida et al., 2023)Japan/202350/MPegfilgrastim/1 day/neutropeniaNeuroblastoma8No treatmentResolved in within 10 days/NO50 (Masuda et al., 2023)Japan/202380/MPegfilgrastim/4 days/neutropeniaBladder cancer6SteroidResolved in within 3 days/NO51 (Koyama et al., 2021)Japan/202383/FPegfilgrastim/3 days/prophylaxisdiffuse large B-cell lymphoma3CelecoxibResolved in within 7 days/NO52 (Lee et al., 2020)Korea/202045/FPegfilgrastim/5 days/neutropeniaBreast cancer12SteroidResolved in within 1 week/NOFilgrastim/1 day/neutropenia10Resolved in within 2 weeks / NO53 (Lee et al., 2020)Korea/202066/FPegflgrastim/3 days/neutropeniaBreast cancer13SteroidResolved in within 1 week/NO54 (Lee et al., 2020)Korea/202049/FPegfilgrastim/1 day/neutropeniaBreast cancer15SteroidResolved in within 1 week/NO55 (Lee et al., 2020)Korea/202050/FPegfilgrastim/1 day/neutropeniaBreast cancer12SteroidResolved in within 1 week/NO56 (Lee et al., 2020)Korea/202059/FPegfilgrastim/1 day/neutropeniaBreast cancer17SteroidResolved in within 1 week/NO57 (Lee et al., 2020)Korea/202053/FPegfilgrastim/4 days/neutropeniaBreast cancer14SteroidResolved in within 1 week/NO58 (Tane et al., 2024)Japan/202143/FPegfilgrastim/1 day/prophylaxisBreast cancer5SteroidResolved in within 18 days/NO59 (Ito et al., 2023)Japan/202373/MPegfilgrastim/1 day/prophylaxisSmall-cell lung cancer12NSAIDSResolved in within 16 days/NO60 (Ito et al., 2024)Japan/202467/FPegfilgrastim/1 day/prophylaxisBreast cancer7No treatmentResolved in within 19 days/NO61 (Sasaki et al., 2019)Japan/201861/FPegfilgrastim/1 day/neutropeniaBreast cancer1No treatmentResolved in within 10 days/NO62 (Sasaki et al., 2019)Japan/201972/FPegfilgrastim/1 day/neutropeniaBreast cancer5No treatmentResolved in within 14 days/NO63 (Hoshina and Takei, 2019)Japan/202455/MFilgrastim/10 days/prophylaxisDiffuse large B-cell lymphoma8SteroidSteroidImprovement rapid/NOLenograstim/9 days/prophylaxis5Resolved in within 30 days / NO64 (Kawahara et al., 2020)Japan/201969/MPegfilgrastim/1 day/prophylaxisDiffuse large B-cell lymphoma13No treatmentResolved in within 7 days/NO65 (Kawahara et al., 2020)Japan/201962/FPegfilgrastim/1 day/prophylaxisDiffuse large B-cell lymphoma11No treatmentSteroidResolved in within 18 days/NO Pegfilgrastim/1 day/prophylaxis12Resolved in within 14 days/NO66 (Saito et al., 2021)Japan/202071/FPegfilgrastim/1 day/prophylaxisOvarian cancer11No treatmentNo treatmentImprovement rapid/NOPegfilgrastim/1 day/prophylaxis11Resolved in within 27 days / NO67 (Nitta et al., 2021)Japan/202171/FPegfilgrastim/1 day/prophylaxisIntrahepatic cholangiocarcinoma7SteroidResolved in within 21 days/NO68 (Jimbo et al., 2021)Japan/202172/MPegfilgrastim/1 day/prophylaxisProstatic cancer10SteroidResolved in within 18 days/NO69 (Singh et al., 2022)Japan/202158/FPegfilgrastim/2 days/prophylaxisBreast cancer8No treatmentResolved in within 26 days/NO70 (Takahashi et al., 2022)USA/202258/FPegfilgrastim/1 days/prophylaxisDuodenal adenocarcinoma7NASIDsResolved in within 12 days/NO71 (Matsumoto et al., 2022)Japan/202255/FPegfilgrastim/1 days/prophylaxisPancreatic cancer7SteroidResolved in within 2 days/NO72 (Mukai et al., 2020)Japan/202263/FPegfilgrastim/1 days/prophylaxisBreast cancer7No treatmentResolved in within 20 days/NO73 (Shiraki et al., 2022)Japan/202270/FPegfilgrastim/1 days/prophylaxisBreast cancer8SteroidResolved in within 445 days/Aortic dissection Detailed summary of all G-CSF-induced aortitis symptoms in patients from case report. 2.3 Statistical analysis Baseline characteristics were described as numbers and percentages for all patients treated with G-CSF. Continuous variables were presented as mean ± standard deviation (M±SD). Categorical variables were presented as percentages. All statistical analysis was performed using Graphpad Prism version 8.0.2. 3 Results 3.1 Frequency and clinical information related to G-CSF-induced aortitis The characteristics of the patients were presented in Table 2. There were 58 women and 14 men, with a mean age of 61.83 years ±10.30 (SD) (age range, 40–80 years) at the occurrence of adverse events related to aortitis. Patients with G-CSF-induced aortitis were predominantly female (male, 19.4%; female, 80.6%). The annual trends in the incidence of G-CSF-induced aortitis are shown in Figure 1, showing that the incidence of G-CSF-induced aortitis increased each year until 2020. Figure 2 shows the relationship between the incidence of G-CSF-induced aortitis and global distribution. The countries with the highest incidence of G-CSF-induced aortitis are Japan (50 cases, 69.4%), South Korea (6 cases, 8.3%) and Finland (6 cases, 8.3%). A total of 72 patients had a medical or prophylactic aim for filgrastim (n = 22), pegfilgrastim (n = 52), lenograstim (n = 5) or lipegfilgrastim (n = 3) during the identification period (Table 2). Of all, pegfilgrastim was characterized by the highest frequency (63.4%) of arteritis. Patients with G-CSF-induced aortitis of these four types were remarkably similar in terms of sex, age and time to onset. Patients who use filgrassim (CRP 26.06 ± 15.39 mg/dL), pegfililgrassim (CRP 24.81 ± 9.65 mg/dL), and lenograstim (CRP 10.45 ± 9.914 mg/dL) all presented varying degrees of elevated serum CRP levels (Table 3). Unfortunately, no CRP related data were provided for the four cases using lipegfilgrastim. In addition, Patients with G-CSF-induced aortitis of these four types were similar in clinical manifestations, such as fever, chest pain, abdominal pain, neck pain, back pain, earache, sore throat, headache and myalgia, etc. Meanwhile, the four types of G-CSF-induced aortitis also exhibited similarities in their common occurrence sites, all of which were prone to occur in the aortic arch, abdominal aorta, and thoracic aorta, etc. TABLE 2Baseline characteristics of Reported Patients.CharacteristicAortitis (n = 72)Sex Female, n (%)58 (80.6)Male, n (%)14 (19.4)Age, mean (±SD) years61.83 (10.30)Total no. of G-CSF Filgrastim, n (%)22 (26.8)Pegfilgrastim, n (%)52 (63.4)Lenograstim, n (%)5 (6.1)Lipegfilgrastim, n (%)3 (3.7)SD = Standard deviation Baseline characteristics of Reported Patients. SD = Standard deviation The annual trends in the number of G-CSF administrations. The distribution of G-CSF-induced aortitis in countries around the world. TABLE 3Baseline demographic characteristics of four types of g-CSFFilgrastimPegfilgrastimLenograstimLipegfilgrastimAge, mean (±SD) years65.05 ± 11.7260.61 ± 9.6655 ± 9.9355 ± 15.01SexFemale164243Male61010Time to onset (days ± SD)11.73 ± 12.728.46 ± 4.166.67 ± 1.536.5 ± 3.10Body temperature (°C)38.55 ± 0.780738.67 ± 0.686539.8 a NACRP (mg/dL)26.06 ± 15.3924.81 ± 9.6510.45 ± 9.914NASD = standard deviation; CRP = C-reactive protein; NA, No detailed data available. a There is only one detailed data. Baseline demographic characteristics of four types of g-CSF SD = standard deviation; CRP = C-reactive protein; NA, No detailed data available. There is only one detailed data. The relationship between the occurrence of G-CSF-induced aortitis and background diseases were shown in Figure 3. Apart from healthy stem cell donors (3 cases, 4.17%), G-CSF-induced aortitis was primarily found in patients with underlying malignancies (69 cases, 95.83%). Among them, the most common malignancies were breast cancer (31 cases, 43.06%), diffuse large B-cell lymphoma (7 cases, 9.72%) and uterine cancer (6 cases, 8.33%). The background chemotherapeutic agents for G-CSF-induced aortitis were shown in Table 4 and Figure 4. Common agents included docetaxel (26 cases), cyclophosphamide (14 cases), doxorubicin (10 cases) and carboplatin (10 cases), followed by cisplatin (7 cases), paclitaxel (7 cases), etoposide (7 cases) and trastuzumab (7 cases). Graph shows cancer types among patients with G-CSF-induced aortitis. TABLE 4Chemotherapeutic agents used in patients with g-CSF-induced aortitis.Chemotherapy drugsAllDocetaxel26Cyclophosphamide14Doxorubicin10Carboplatin10Cisplatin8Paclitaxel7Trastuzumab7Etoposide75-fluorouracil6Rituximab6Epirubicin5Pertuzumab4Irinotecan4Vincristine4Oxaliplatin3Levofolinate Calcium3Gemcitabine2Duvalizumab1Panitumumab1Venetoclax1Azacytidine1Cytarabine1Bevacizumab1Note. Unless otherwise indicated, data are numbers of patients. Chemotherapeutic agents used in patients with g-CSF-induced aortitis. Note. Unless otherwise indicated, data are numbers of patients. Graph shows the frequency of primary aortitis in patients with different chemotherapy regimen. 3.2 Clinical presentation and Radiologic findings of G-CSF-induced aortitis The frequency of G-CSF-induced aortitis in patients with different chemotherapy regimens was shown in Figure 4. The chemotherapy regimen that was most frequently associated with the occurrence of arteritis was docetaxel and the combination of docetaxel and cyclophosphamide. The onset of aortitis may be presented as symptomatic or be asymptomatic. Symptomatic patients mainly presented with fever, chest pain, back pain, abdominal pain, neck pain, and sore throat, etc (Table 3). The blood test results revealed an elevated CRP (Table 3). The lesions were primarily located at the aortic arch in 26 cases (36.11%), abdominal aorta in 19 cases (26.39%) and thoracic aorta in 16 cases (22.22%) (Figure 5). The blood culture tests of all patients were negative. None of these patients met diagnostic criteria for conditions such as macro-arteritis, granuloma with polyangiitis, or giant cell arteritis. None of the patients had a history of IgG4-related diseases, and there were no other organ involvements attributed to IgG4-related diseases post the arteritis event. Graph shows distribution of G-CSF-induced aortitis at CT. Vertical axis indicates location of the aorta and its branches, and abscissa indicates the number of patients with G-CSF-induced aortitis. BCA = brachiocephalic artery; CCA = common carotid artery; SCA = subclavian artery. Among the 72 patients with G-CSF-induced aortitis, 68 cases (96%) were symptomatic, while the remaining 4 (6%) were asymptomatic. Symptomatic patients with steroids or nonsteroidal anti-inflammatory drugs (NSAIDs) treatment exhibited an improvement in symptoms within an average of 15.26 ± 15.48 days, while untreated patients needed an average of 19.25 ± 10.23 days to achieve remission. Forty-seven patients accepted corticosteroids therapy, five were treated with NSAIDs, and the remaining patients did not receive any medication treatment, merely undergoing G-CSF discontinuation and conservative observation. For the 4 asymptomatic patients, after observation, the inflammatory changes in the aortitis also recovered. The specific recovery time of three asymptomatic patients with arteritis was unknown, and one asymptomatic patient recovered in 27 days. Five patients developed recurrent aortitis due to re-using the same type of G-CSF. Despite switching to another type of G-CSF, one patient still developed aortitis. CT findings indicated recovery in most cases, but one case led to aortic aneurysm, and two case led aortic dissection. 4 Discussion Among all the published case reports, G-CSF-induced aortitis tended to affect elderly women over the age of 60. In addition, the cases of male G-CSF-induced aortitis observed in this review may reflect a higher likelihood of occurrence of prostatic cancer in men. The reason why G-CSF-induced aortitis is more likely to occur in females compared to males is not yet clear, so more samples would be needed to verify the gender differences in G-CSF-induced aortitis. Moreover, G-CSF-induced aortitis was frequently observed in patients with breast cancer as the primary tumor and in patients who received the anticancer drugs docetaxel and cyclophosphamide. The two drugs were used as combination therapy for patients with esophageal cancer (docetaxel and cyclophosphamide). Although, several reports have discussed the relationship between G-CSF-induced aortitis and anticancer drugs, especially docetaxel (Hoshina and Takei, 2021; Taimen et al., 2020). Our finding was that more patients with G-CSF induced aortitis have been using docetaxel, which is consistent with previous reports. However, the causal relationship between docetaxel and G-CSF-induced aortitis remains unclear. In addition, the drug instructions indicate that cyclophosphamide may lead to adverse reactions such as vasculitis. Therefore, when G-CSF is necessary, close attention should be paid to the clinical symptoms of patients when using cyclophosphamide in combination. We discovered that over three-fourths of all cases occured in Asian populations, particularly in Japan and Korea. Human leucocyte antigen (HLA) as the genetic system with the richest polymorphism in humans, plays a crucial role in intercellular recognition, antigen recognition, and antigen presentation, resulting in different susceptibility of HLA genes to diseases. Evidence shows that HLA-DRB1*09:01 is one of the most common HLA-DRB1 alleles in Asians but is rare in European and American populations (Tsuchiya, 2013). Meanwhile, HLA-DRB1*09:01 has been shown to be associated with antineutrophil cytoplasmic antibody-associated vasculitis in Japan (Tsuchiya, 2013). In addition, previous literature has shown that the HLA-DRB1*04 and DRB1*07 alleles were strongly associated with aortitis in a Chinese Han population (Dang et al., 2002). The reason why G-CSF-induced aortitis was more common in Asian regions such as Japan and South Korea may be related to susceptibility genes in the Asian population that predispose to the development of aortitis. However, there is no evidence to support the correlation between HLA genes and G-CSF-induced aortitis. Therefore, it is necessary that further research will be conducted on the correlation between aortitis and HLA genes in populations prone to G-CSF- induced aortitis. Our research findings also provided a deeper understanding of asymptomatic G-CSF-induced aortitis, which occurred in 4 out of 72 cases. These 4 asymptomatic patients with aortitis were found to have occurred between 1 and 2 weeks after using G-CSF through CT examination. Due to early detection, only G-CSF was discontinued for these asymptomatic patients and they did not receive treatment with glucocorticoids or NSAIDs. If G-CSF failed to discontinue medication timely in this type of patient, it was not clear whether it would lead to severe symptoms in the later stage. Therefore, considering the rarity of asymptomatic vasculitis and the issue of health economics, whether it is necessary to use ultrasound or CT for screening is not yet conclusive. Currently, two types of G-CSF are clinically available, one being short-acting G-CSF including filgrastim and lenograstim, and another type being long-acting G-CSF including pegfilgrastim and lipegfilgrastim. We found that the proportion of pegfilgrastim was highest in G-CSF-induced aortitis cases, followed by filgrastim. In terms of pharmacokinetics, the half-life of filgrastim is 3.5 h, and that of pegfilgrastim is 33.2 h (Zamboni, 2003). Compared with filgrastim, pegfilgrastim was more likely to induce aortic inflammation, potentially due to its longer pharmacological effect. G-CSF-induced aortitis lesions were reported to be common in the aortic arch and proximal bifurcation. The distribution patterns of the aortitis are consistent with the findings of a single-center analysis by Takamatsu et al. (Lee et al., 2020). Owing to the unique anatomical structure of the aortic arch, hemodynamic instability heightens the risk of aortic dissection occurring at this location (Williams et al., 2022). Therefore, for patients with arteritis in the aortic arch and its branches, the treating physicians should be vigilant and actively treat to prevent the occurrence of aortic aneurysm and aortic dissection. According to etiology, arteritis can be broadly classified as infectious and non-infectious (Benhuri et al., 2020). However, the underlying mechanism of aortitis-induced by G-CSF is still unclear. Functionally, G-CSF is a growth factor that regulates many aspects of neutrophil biology, including proliferation, differentiation, release, trafficking, and survival of granulocytes (Martin et al., 2021). However, in autoimmune and inflammatory diseases, the neutrophil response must be strictly regulated, as excessive recruitment and activation, or prolonged neutrophil survival time, can lead to chronic inflammation and sometimes irreversible organ damage (Martin et al., 2021). In this study, pegfilgrastim had the highest proportion of arterial inflammation, which may be related to its longer biological half-life. G-CSF-induced aortitis exhibited good responsiveness to corticosteroids or NSAIDs and had a favorable prognosis. However, among all the collected cases, 2 cases had aortic dissection (Shiraki et al., 2022; Sato et al., 2017) and 1 case had aortic aneurysm (Miller et al., 2016). One case was a 58-year-old healthy male who was injected with filgrastim to donate bone marrow stem cells. Six months later, an iliac artery aneurysm was discovered (Miller et al., 2016). In the other two cases, after corticosteroids treatment, the symptoms of G-CSF-induced aortitis improved, but CT scans revealed aortic dissection (Shiraki et al., 2022; Sato et al., 2017). These cases suggested that even after the symptoms improve during corticosteroids therapy, there was still a risk of developing aortic dissection. Therefore, before corticosteroids reduction, it should be recommended to recheck CT to clarify the recovery status of arteritis. There is controversy concerning the acceptability of re-administration or change dosage form of G-CSF in patients with a history of G-CSF-induced aortitis. Among all collected cases, three underwent pegfilgrastim re-administration later; three of the patients exhibited recurrence of pegfilgrastim-induced aortitis. One case who had clinically diagnosed pegfilgrastim-induced aortitis, after switching to filgrastim, still developed G-CSF-induced aortitis. One case who had clinically diagnosed filgrastim-induced aortitis, after switching to lenograstim, also reappeared with G-CSF-induced aortitis. This indicated that patients with a history of G-CSF-induced aortitis, whether through repeated use or changes in dosage form, cannot rule out the possibility of recurrent G-CSF-induced aortitis. However, considering the reporting bias, further validation of clinical data is needed for this possibility. In conclusion, regardless of the dosage form of G-CSF, there is a risk of leading to arteritis. Due to the increased use of prophylactic treatment for chemotherapy-related neutropenia, the frequency of G-CSF-induced aortitis had also increased. In addition, G-CSF-induced aortitis also occured in healthy stem cell donors. Especially, asymptomatic patients with G-CSF-induced aortitis faced a greater risk of being missed by the attending physician. Given the regional characteristics of G-CSF-induced aortitis, it is recommended that physicians should pay close attention to the Asian population, especially elderly women after using G-CSF, to prevent the occurrence of complications of vasculitis.